ANT308 TFA

ANT308 TFA serves as an antagonist for the vasoactive intestinal peptide (VIP receptor) . It significantly enhances the activation and proliferation of T cells. By inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin, ANT308 TFA impedes the migration and metastasis of melanoma cells and induces apoptosis. This compound is applicable in research related to acute myeloid leukemia (AML) and uveal melanoma (UVM) .